Groen, Harry J. M.
,
van der Heijden, Erik H. F. M.
Klinkenberg, Theo J.
Biesma, Bonne
Aerts, Joachim
Verhagen, Ad
Kloosterziel, Corinne
Pieterman, Remge
van den Borne, Ben
Smit, Hans J. M.
Hoekstra, Otto
Schramel, Frans M. N. H.
van der Noort, Vincent
van Tinteren, Harm
Smit, Egbert F.
Dingemans, Anne-Marie C.
Article History
Received: 1 November 2018
Revised: 13 June 2019
Accepted: 4 July 2019
First Online: 24 July 2019
Competing interests
: H.J.M.G., E.F.S. and A.-M.D. were on the advisory boards of Lilly and Roche. The remaining authors authors declare no competing interests.
: The study was approved by the medical ethics committee of the University Medical Center Groningen in the Netherlands (METc nr. 2007-076). All patients gave informed consent. The study was registered at NTR 1250 (new ID 1205). The study was performed in accordance with the Declaration of Helsinki.
: This work was financially supported with regard to the drug supply and data management by Eli Lilly, Amgen, Roche, and the Dutch Cancer Society.
: The study should be published according to our protocol that was approved by the medical ethics committee.
: The dataset used and analysed in the current study is available from the corresponding author on reasonable request. All data are stored at the NVALT Data Center at the National Cancer Center Netherlands.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).